Search results (226)
« Back to PublicationsSerological thresholds of risk reduction for infant group B streptococcus disease
Preprint
Cantrell L. et al, (2026)
Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.
Journal article
Hagedoorn NN. et al, (2026), Vaccine, 85
Correction: Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.
Journal article
Walker J. et al, (2026), PLoS Negl Trop Dis, 20
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
Journal article
Bijukchhe SM. et al, (2026), Lancet Infect Dis
Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections
Preprint
Hagedoorn N. et al, (2026)
Maternal iron status and total immunoglobulin-G influence transplacental antibody transfer across eight diverse geographical settings.
Journal article
Tiley KS. et al, (2026), Vaccine, 73
"Now that the baby is out, I can be vaccinated": a qualitative study on COVID-19 vaccine hesitancy in pregnant women in Kilifi, Kenya.
Journal article
Koech A. et al, (2026), Front Public Health, 14
Modeling Indirect Protection from Typhoid Conjugate Vaccines in the TyVAC-Bangladesh Trial
Preprint
Walker J. et al, (2025)
A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.
Journal article
Williams LR. et al, (2025), Vaccine, 67
A novel approach for estimating vaccine efficacy for infections with multiple outcomes: application to a COVID-19 vaccine trial
Journal article
Williams LR. et al, (2025), AJE Advances: Research in Epidemiology, 1
Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.
Journal article
Walker J. et al, (2025), PLoS Negl Trop Dis, 19
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).
Journal article
Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal article
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

